Ahmann AJ, Capehorn M, Charpentier G, et al
A variety of anti-obesity organizations have also warned against taking compounded GLP-1 meds, citing the lack of regulatory oversight
It is a demonstration model designed by the Centers for Medicare and Medicaid Services (CMS) to test whether structured GLP-1 access, combined with lifestyle interventions, can improve health outcomes while remaining fiscally sustainable
Both the semaglutide and tirzepatide shortages that made compounding legally available were declared resolved in 2024 and 2025, the compounding wind-down deadlines have passed, and in April 2026 the FDA proposed closing the remaining legal pathway entirely
253,254 GLP-1 usually refers to GLP-1(7-36), a peptide chain consisting of 36 amino acids and the primary active molecule